Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CYDY NASDAQ:RCKT NASDAQ:UPXI NYSEAMERICAN:XTNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYDYCytoDyn$0.26+0.1%$0.29$0.10▼$0.49$327.54M1.372.65 million shs1.26 million shsRCKTRocket Pharmaceuticals$3.22+1.7%$3.19$2.19▼$18.89$346.90M0.63.53 million shs1.31 million shsUPXIUpexi$7.29+11.7%$6.33$1.90▼$22.57$429.01M-0.534.00 million shs6.84 million shsXTNTXtant Medical$0.64-1.8%$0.63$0.33▼$0.78$88.90M-0.22118,839 shs83,117 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYDYCytoDyn-0.08%-5.49%-13.37%-8.84%+68.05%RCKTRocket Pharmaceuticals-3.07%-4.82%-3.66%+9.12%-81.54%UPXIUpexi+13.17%+6.01%-9.68%+100.00%+58.26%XTNTXtant Medical-0.39%+3.04%+1.16%-6.56%-3.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYDYCytoDyn$0.26+0.1%$0.29$0.10▼$0.49$327.54M1.372.65 million shs1.26 million shsRCKTRocket Pharmaceuticals$3.22+1.7%$3.19$2.19▼$18.89$346.90M0.63.53 million shs1.31 million shsUPXIUpexi$7.29+11.7%$6.33$1.90▼$22.57$429.01M-0.534.00 million shs6.84 million shsXTNTXtant Medical$0.64-1.8%$0.63$0.33▼$0.78$88.90M-0.22118,839 shs83,117 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYDYCytoDyn-0.08%-5.49%-13.37%-8.84%+68.05%RCKTRocket Pharmaceuticals-3.07%-4.82%-3.66%+9.12%-81.54%UPXIUpexi+13.17%+6.01%-9.68%+100.00%+58.26%XTNTXtant Medical-0.39%+3.04%+1.16%-6.56%-3.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYDYCytoDyn 0.00N/AN/AN/ARCKTRocket Pharmaceuticals 2.41Hold$16.73420.48% UpsideUPXIUpexi 3.50Strong Buy$15.50112.59% UpsideXTNTXtant Medical 3.00Buy$1.50136.22% UpsideCurrent Analyst Ratings BreakdownLatest XTNT, UPXI, RCKT, and CYDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025RCKTRocket PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $10.008/20/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/13/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.008/8/2025RCKTRocket PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$10.00 ➝ $8.008/4/2025UPXIUpexiAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.007/25/2025RCKTRocket PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$11.00 ➝ $10.007/25/2025RCKTRocket PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$9.00 ➝ $4.007/24/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $12.007/24/2025RCKTRocket PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold(Data available from 10/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYDYCytoDynN/AN/A$0.00 per share78.03($0.08) per shareN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/AUPXIUpexi$15.81M27.16N/AN/A$1.01 per share7.22XTNTXtant Medical$117.27M0.76N/AN/A$0.31 per share2.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYDYCytoDyn$3.74M$0.0126.03∞N/AN/AN/A-4.40%10/15/2025 (Estimated)RCKTRocket Pharmaceuticals-$258.75M-$2.51N/AN/AN/AN/A-65.11%-55.99%11/6/2025 (Estimated)UPXIUpexi-$13.68MN/A0.00∞N/A-86.54%-54.33%-31.28%N/AXTNTXtant Medical-$16.45M-$0.13N/A∞N/A-3.59%-10.12%-4.67%11/11/2025 (Estimated)Latest XTNT, UPXI, RCKT, and CYDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025RCKTRocket Pharmaceuticals-$0.57-$0.59-$0.02-$0.62$4.36 millionN/A7/25/2025Q4 2025CYDYCytoDynN/A-$0.01N/A-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYDYCytoDynN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/AXTNTXtant MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYDYCytoDynN/A0.250.25RCKTRocket Pharmaceuticals0.056.396.39UPXIUpexiN/A1.741.71XTNTXtant Medical0.462.471.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYDYCytoDyn5.06%RCKTRocket Pharmaceuticals98.39%UPXIUpexi5.68%XTNTXtant Medical69.33%Insider OwnershipCompanyInsider OwnershipCYDYCytoDyn0.54%RCKTRocket Pharmaceuticals24.76%UPXIUpexi4.42%XTNTXtant Medical10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYDYCytoDyn201.26 billion1.25 billionNot OptionableRCKTRocket Pharmaceuticals240107.90 million81.19 millionOptionableUPXIUpexi13058.89 million56.29 millionOptionableXTNTXtant Medical120140.00 million125.44 millionNot OptionableXTNT, UPXI, RCKT, and CYDY HeadlinesRecent News About These CompaniesXtant Medical (NYSEAMERICAN:XTNT) Share Price Passes Above 200 Day Moving Average - Here's WhyOctober 2 at 3:19 AM | marketbeat.comXtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above 200-Day Moving Average - Here's What HappenedSeptember 24, 2025 | marketbeat.comXtant Medical (NYSEAMERICAN:XTNT) Stock Passes Above 200-Day Moving Average - Here's WhySeptember 17, 2025 | marketbeat.comXtant Medical (NYSEAMERICAN:XTNT) Shares Pass Above 200-Day Moving Average - Should You Sell?September 8, 2025 | marketbeat.comXtant Medical to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | prnewswire.comEarnings To Watch: Xtant Medical Holdings Inc (XTNT) Reports Q2 2025 ResultAugust 13, 2025 | finance.yahoo.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comXtant Medical Reports Strong Q2 2025 ResultsAugust 13, 2025 | msn.comXtant Medical Holdings, Inc.: Xtant Medical Reports Second Quarter 2025 Financial ResultsAugust 12, 2025 | finanznachrichten.deXtant Medical Holdings, Inc. (XTNT) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comXtant Medical Reports Second Quarter 2025 Financial ResultsAugust 12, 2025 | prnewswire.comEarnings Preview For Xtant Medical HldgsAugust 11, 2025 | benzinga.comXtant Medical to Attend the CG 45th Annual Growth ConferenceAugust 6, 2025 | prnewswire.comXtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025August 5, 2025 | prnewswire.comXtant Medical Partners With B2i Digital to Educate Investors on Its Orthobiologics Innovation and Market OpportunityJuly 29, 2025 | finance.yahoo.comXtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion SpineJuly 8, 2025 | prnewswire.comXtant Medical Holdings Inc Share Price (XTNT.US)June 4, 2025 | lse.co.ukXtant Medical Announces the Launch of OsteoFactor Pro™May 28, 2025 | prnewswire.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comXtant Medical Holdings, Inc.: Xtant Medical Reports First Quarter 2025 Financial ResultsMay 13, 2025 | finanznachrichten.deXtant Medical Holdings Inc (XTNT) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ...May 13, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXTNT, UPXI, RCKT, and CYDY Company DescriptionsCytoDyn OTCMKTS:CYDY$0.26 +0.00 (+0.08%) As of 02:48 PM EasternCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Rocket Pharmaceuticals NASDAQ:RCKT$3.22 +0.06 (+1.74%) As of 03:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Upexi NASDAQ:UPXI$7.29 +0.76 (+11.65%) As of 03:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.Xtant Medical NYSEAMERICAN:XTNT$0.64 -0.01 (-1.76%) As of 03:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How Berkshire's OxyChem Buy Cements Its Long-Term Strength Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? Datavault AI: The New AI Contender Backed by Big Funding Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t Worry Rocket Lab's Electron: The Quiet Workhorse Powering Momentum CoreWeave: Why the New King of AI Infrastructure Has Room to Run Palantir Stock Eyes New Highs, Boosted by Boeing Partnership Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
